HER2-positive Breast Cancer, Metastatic Breast Cancer
Conditions
Brief summary
Trastuzumab combined with chemotherapy has been approved as the first line therapy in HER2+ metastatic breast cancer. When patients experienced progression beyond trastuzumab containing therapy, T-DM1 is considered as the second line therapy followed by trastuzumab plus any other chemotherapeutic agents or lapatinib plus capecitabine. A biosimilar drug is a biological product that is highly similar to a licensed biological product, with no clinically meaningful differences in terms of safety, purity, or potency. Several trastuzumab biosimilar products have been approved after efficacy and safety studies which were usually as the first line setting with taxane combined. Even though trastuzumab biosimilar drugs demonstrated similarity of equivalence with trastuzumab in these studies, the efficacy of their second use beyond progression with other chemotherapeutic agents has not been tested yet. In addition, the investigators don't have any data regarding possible cross reactivity between trastuzumab and trastuzumab biosimilar drugs. In this study, the investigators plan multicenter phase II clinical trial to test the efficacy, safety and immunogenicity of trastuzumab biosimilar, Herzuma® in combination with TPC in patients with HER2+ metastatic breast cancer who progressed after 2 or more HER-2 directed chemotherapy.
Interventions
DRUGHerzuma
Herzuma + Treatment of Physician's Choice
Sponsors
National Cancer Center, Korea
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
19 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Patient is an adult, ≥ 19 years old at the time of informed consent. 2. Patient has histologically and/or cytologically confirmed diagnosis of HER2-positive breast cancer (HER-2/neu 3+ as defined by immunohistochemistry and/or HER-2/neu gene amplification as defined by fluorescence in situ hybridization). 3. Metastatic or unresectable disease documented on diagnostic imaging studies. 4. Prior 2 or more HER-2 directed therapy for metastatic disease is mandatory. 5. Patient must have at least one measurable or evaluable lesion according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v 1.1) 6. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 1 7. Adequate bone marrow and organ function including: a) WBC ≥ 3500/ml; b) Platelets ≥ 100,000/ul; c) Hemoglobin \>9.0 g/dl; d) Total bilirubin ≤ 1.5x ULN; e) AST and ALT \< 2.5 x ULN; f) Alkaline phosphatase \<2.5x ULN; g) Creatinine ≤ 1.5x ULN or CCr \>60 ml/min for patients with abnormal serum Cr level function. 8. Life expectance longer than 3 months 9. Patient has an adequate left ventricular ejection function of at least 55 % at baseline, as measured by echocardiography. 10. Written informed consent
Exclusion criteria
1. Patient is pregnant or lactating, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive human chorionic gonadotropin (hCG) laboratory test. 2. Patient has symptomatic and unstable CNS metastases, except for treated brain metastases. Treated brain metastases are defined as having no evidence of progression or hemorrhage after treatment and no ongoing requirement for dexamethasone, as ascertained by clinical examination and brain imaging (MRI or CT) during the screening period. Anticonvulsants (stable dose) are allowed. 3. Active and clinically significant bacterial, fungal or viral infection including hepatitis B (HBV), hepatitis C (HCV), known human immunodeficiency virus syndrome (HIV) or acquired immunodeficiency syndrome (AIDS)-related illness. Baseline viral assessment is not required in patients with no known infection. 4. Major surgery within 4 weeks of first dose of investigational product or not fully recovered from any side effects of previous procedures. 5. Any other malignancy within 3 years prior to first dose of investigational product except for adequately treated basal cell or squamous cell skin cancer, or carcinoma in situ of the cervix. 6. QTc interval \>480 msec (based on the mean value of the triplicate ECGs), family or personal history of long or short QT syndrome, Brugada syndrome or known history of QTc prolongation or Torsade de Pointes. 7. Any of the following within 6 months of first dose of investigational product myocardial infarction, severe/unstable angina, ongoing cardiac dysrhythmias of NCI CTCAE v. 5.0 Grade ≤2, atrial fibrillation of any grade, coronary/peripheral artery bypass graft, symptomatic congestive heart failure, cerebrovascular accident including transient ischemic attack, or symptomatic pulmonary embolism. 8. History of symptomatic interstitial pneumonitis. 9. Patients with a history of hypersensitivity reactions to trastuzumab, rodent-derived proteins, or components of trastuzumab. 10. Other severe acute or chronic medical or psychiatric condition, including recent (within the past year) or active suicidal ideation or behavior, or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the patient inappropriate for entry into this study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Progression Free Survival | 6 months after last patient enrollment | defined as the time from study entry until the first observation of existing disease progression according to the above schedule or death due to any cause. |
Countries
South Korea
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Herzuma Herzuma + TPC
Herzuma: Herzuma + Treatment of Physician's Choice | 109 |
| Total | 109 |
Baseline characteristics
| Characteristic | Herzuma |
|---|---|
| Age, Continuous | 55 years |
| Ethnicity (NIH/OMB) Hispanic or Latino | 0 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 109 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants |
| Region of Enrollment South Korea | 109 participants |
| Sex: Female, Male Female | 109 Participants |
| Sex: Female, Male Male | 0 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | 37 / 109 |
| other Total, other adverse events | 29 / 109 |
| serious Total, serious adverse events | 42 / 109 |
Outcome results
Primary
Progression Free Survival
defined as the time from study entry until the first observation of existing disease progression according to the above schedule or death due to any cause.
Time frame: 6 months after last patient enrollment
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Herzuma | Progression Free Survival | 4.6 months |